Alberts Arnout R, Schoots Ivo G, Bokhorst Leonard P, Drost Frank-Jan H, van Leenders Geert J, Krestin Gabriel P, Dwarkasing Roy S, Barentsz Jelle O, Schröder Fritz H, Bangma Chris H, Roobol Monique J
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Eur Urol. 2018 Mar;73(3):343-350. doi: 10.1016/j.eururo.2017.06.019. Epub 2017 Jun 21.
The harm of screening (unnecessary biopsies and overdiagnosis) generally outweighs the benefit of reducing prostate cancer (PCa) mortality in men aged ≥70 yr. Patient selection for biopsy using risk stratification and magnetic resonance imaging (MRI) may improve this benefit-to-harm ratio.
To assess the potential of a risk-based strategy including MRI to selectively identify men aged ≥70 yr with high-grade PCa.
DESIGN, SETTING, AND PARTICIPANTS: Three hundred and thirty-seven men with prostate-specific antigen ≥3.0 ng/ml at a fifth screening (71-75 yr) in the European Randomized study of Screening for Prostate Cancer Rotterdam were biopsied. One hundred and seventy-nine men received six-core transrectal ultrasound biopsy (TRUS-Bx), while 158 men received MRI, 12-core TRUS-Bx, and fusion TBx in case of Prostate Imaging Reporting and Data System ≥3 lesions.
The primary outcome was the overall, low-grade (Gleason Score 3+3) and high-grade (Gleason Score ≥ 3+4) PCa rate. Secondary outcome was the low- and high-grade PCa rate detected by six-core TRUS-Bx, 12-core TRUS-Bx, and MRI ± TBx. Tertiary outcome was the reduction of biopsies and low-grade PCa detection by upfront risk stratification with the Rotterdam Prostate Cancer Risk Calculator 4.
Fifty-five percent of men were previously biopsied. The overall, low-grade, and high-grade PCa rates in biopsy naïve men were 48%, 27%, and 22%, respectively. In previously biopsied men these PCa rates were 25%, 20%, and 5%. Sextant TRUS-Bx, 12-core TRUS-Bx, and MRI ± TBx had a similar high-grade PCa rate (11%, 12%, and 11%) but a significantly different low-grade PCa rate (17%, 28%, and 7%). Rotterdam Prostate Cancer Risk Calculator 4-based stratification combined with 12-core TRUS-Bx ± MRI-TBx would have avoided 65% of biopsies and 68% of low-grade PCa while detecting an equal percentage of high-grade PCa (83%) compared with a TRUS-Bx all men approach (79%).
After four repeated screens and ≥1 previous biopsies in half of men, a significant proportion of men aged ≥70 yr still harbor high-grade PCa. Upfront risk stratification and the combination of MRI and TRUS-Bx would have avoided two-thirds of biopsies and low-grade PCa diagnoses in our cohort, while maintaining the high-grade PCa detection of a TRUS-Bx all men approach. Further studies are needed to verify these results.
Prostate cancer screening reduces mortality but is accompanied by unnecessary biopsies and overdiagnosis of nonaggressive tumors, especially in repeatedly screened elderly men. To tackle these drawbacks screening should consist of an upfront risk-assessment followed by magnetic resonance imaging and transrectal ultrasound-guided biopsy.
在70岁及以上男性中,筛查的危害(不必要的活检和过度诊断)通常超过降低前列腺癌(PCa)死亡率的益处。使用风险分层和磁共振成像(MRI)进行活检的患者选择可能会改善这种利弊比。
评估包括MRI在内的基于风险的策略选择性识别70岁及以上高级别PCa男性的潜力。
设计、设置和参与者:在鹿特丹前列腺癌筛查欧洲随机研究的第五次筛查(71 - 75岁)时,对337名前列腺特异性抗原≥3.0 ng/ml的男性进行了活检。179名男性接受了经直肠超声六针活检(TRUS - Bx),而158名男性接受了MRI检查,对于前列腺影像报告和数据系统≥3级病变的情况,接受了12针TRUS - Bx和融合活检。
主要结局是总体、低级别(Gleason评分3 + 3)和高级别(Gleason评分≥3 + 4)PCa发生率。次要结局是经六针TRUS - Bx、12针TRUS - Bx以及MRI ± 活检检测到的低级别和高级别PCa发生率。三级结局是使用鹿特丹前列腺癌风险计算器4进行预先风险分层减少活检和低级别PCa检测的情况。
55%的男性之前接受过活检。未接受过活检的男性中,总体、低级别和高级别PCa发生率分别为48%、27%和22%。在之前接受过活检的男性中,这些PCa发生率分别为25%、20%和5%。六分区TRUS - Bx、12针TRUS - Bx以及MRI ± 活检的高级别PCa发生率相似(分别为11%、12%和11%),但低级别PCa发生率显著不同(分别为17%、28%和7%)。与对所有男性采用TRUS - Bx的方法相比,基于鹿特丹前列腺癌风险计算器4的分层结合12针TRUS - Bx ± MRI - 活检可避免65%的活检和68%的低级别PCa,同时检测到相同比例(83%)的高级别PCa(TRUS - Bx对所有男性的方法为79%)。
在一半男性经过四次重复筛查且≥1次先前活检后,相当比例的70岁及以上男性仍患有高级别PCa。预先风险分层以及MRI和TRUS - Bx的联合应用可在我们的队列中避免三分之二的活检和低级别PCa诊断,同时保持TRUS - Bx对所有男性方法中高级别PCa的检测率。需要进一步研究来验证这些结果。
前列腺癌筛查可降低死亡率,但伴随着不必要的活检和对非侵袭性肿瘤的过度诊断,尤其是在反复筛查的老年男性中。为解决这些缺点,筛查应包括预先风险评估,随后进行磁共振成像和经直肠超声引导活检。